Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score

European Urology

Volumn 70, Issue 5, 2016, Pages 740-748

  Van Neste, Leander ^a   Hendriks, Rianne J ^b   Dijkstra, Siebren ^b   Trooskens, Geert ^c   Cornel, Erik B ^d   Jannink, Sander A ^c   de Jong, Hans ^c   Hessels, Daphne ^c   Smit, Frank P ^c   Melchers, Willem J G ^b   Leyten, Gisèle H J M ^b,e   de Reijke, Theo M ^e   Vergunst, Henk ^f   Kil, Paul ^g   Knipscheer, Ben C ^h   Hulsbergen van de Kaa, Christina A ^b   Mulders, Peter F A ^b   van Oort, Inge M ^b   Van Criekinge, Wim ⁱ   Schalken, Jack A ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MDxHealth   (Belgium)

^d Regional Hospital ZGT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g CPRLab   (Netherlands)

^h Scheper Ziekenhuis   (Netherlands)

ⁱ GHENT UNIVERSITY   (Belgium)

Author keywords

Biologic markers; Logistic models; Messenger RNA; Prostate neoplasms; PSA; Urine

Indexed keywords

DLX1 PROTEIN; HOXC4 PROTEIN; HOXC6 PROTEIN; PCA3 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; TDRD1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; DISTAL-LESS HOMEOBOX PROTEINS; HOMEODOMAIN PROTEIN; HOXC6 PROTEIN, HUMAN; MESSENGER RNA; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; URINE SAMPLING; VALIDITY; GENETICS; HEALTH SERVICE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PREVENTION AND CONTROL; PROCEDURES; PROSTATE; PROSTATE TUMOR; REPRODUCIBILITY; RISK ASSESSMENT; URINE;

AGED; BIOMARKERS, TUMOR; CLINICAL DECISION-MAKING; HOMEODOMAIN PROTEINS; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; NEOPLASM GRADING; PATIENT SELECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84963945093     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.04.012     Document Type: Article

References (30)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. [2] Draisma, G., Etzioni, R., Tsodikov, A., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101 (2009), 374–383.
3. [3] Welch, H.G., Albertsen, P.C., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101 (2009), 1325–1329.
4. [4] Albertsen, P.C., Hanley, J.A., Fine, J., 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005), 2095–2101.
5. [5] Groskopf, J., Aubin, S.M., Deras, I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006), 1089–1095.
6. [6] Gittelman, M.C., Hertzman, B., Bailen, J., et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190 (2013), 64–69.
7. [7] Bussemakers, M.J., van Bokhoven, A., Verhaegh, G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999), 5975–5979.
8. [8] Hessels, D., Klein Gunnewiek, J.M., van Oort, I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003), 8–15 discussion 16.
9. [9] Auprich, M., Chun, F.K., Ward, J.F., et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59 (2011), 96–105.
10. [10] Marks, L.S., Fradet, Y., Deras, I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007), 532–535.
11. [11] Ploussard, G., Haese, A., Van Poppel, H., et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. BJU Int 106 (2010), 1143–1147.
12. [12] Scattoni, V., Lazzeri, M., Lughezzani, G., et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 190 (2013), 496–501.
13. [13] Nordstrom, T., Vickers, A., Assel, M., Lilja, H., Gronberg, H., Eklund, M., Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. Eur Urol 68 (2015), 139–146.
14. [14] Seisen, T., Rouprêt, M., Brault, D., et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate 75 (2015), 103–111.
15. [15] Ferro, M., Bruzzese, D., Perdona, S., et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 413 (2012), 1274–1278.
16. [16] Braun, K., Sjoberg, D.D., Vickers, A.J., Lilja, H., Bjartell, A.S., A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort. Eur Urol 69 (2016), 505–511.
17. [17] Parekh, D.J., Punnen, S., Sjoberg, D.D., et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 68 (2015), 464–470.
18. [18] Leyten, G.H., Hessels, D., Smit, F.P., et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 21 (2015), 3061–3070.
19. [19] Ankerst, D.P., Hoefler, J., Bock, S., et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83 (2014), 1362–1367.
20. [20] Hansen, J., Auprich, M., Ahyai, S.A., et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 63 (2013), 201–209.
21. [21] Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. Clin Chem 61 (2015), 1446–1452.
22. [22] Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3 (2008), 1101–1108.
23. [23] DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
24. [24] Vickers, A.J., Elkin, E.B., Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26 (2006), 565–574.
25. [25] Hendriks, R.J., Dijkstra, S., Jannink, S.A., et al. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin Chem Lab Med 54 (2016), 483–492.
26. [26] Thompson, I.M., Pauler, D.K., Goodman, P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004), 2239–2246.
27. [27] Thompson, I.M., Ankerst, D.P., Chi, C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006), 529–534.
28. [28] Wolters, T., van der Kwast, T.H., Vissers, C.J., et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 34 (2010), 35–43.
29. [29] Stewart, G.D., Van Neste, L., Delvenne, P., et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol 189 (2013), 1110–1116.
30. [30] Roehl, K.A., Antenor, J.A., Catalona, W.J., Serial biopsy results in prostate cancer screening study. J Urol 167 (2002), 2435–2439.